Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial.
Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, Fabregat i Mayol X, Mellado B, Rubio Perez MJ, Alonso Carrion L, Casado Herraez A, Calvo Garcia E, Churruca Galaz C, Arcusa Lanza A, Herrero Ibañez A, Adrover Cebrian E, Poveda Velasco A. Ojeda Gonzalez B, et al. Among authors: arcusa lanza a. Am J Clin Oncol. 2008 Oct;31(5):481-7. doi: 10.1097/COC.0b013e31816d1c7b. Am J Clin Oncol. 2008. PMID: 18838886 Clinical Trial.
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo JA, Bermejo B, Carrasco E, Lluch A; GEICAM. Alba E, et al. Among authors: arcusa lanza a. Ann Oncol. 2012 Dec;23(12):3069-3074. doi: 10.1093/annonc/mds132. Epub 2012 Jun 6. Ann Oncol. 2012. PMID: 22674146 Free article. Clinical Trial.
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors-Health-EpiGEICAM Study.
Lope V, Guerrero-Zotano A, Ruiz-Moreno E, Bermejo B, Antolín S, Montaño Á, Baena-Cañada JM, Ramos Vázquez M, Fernández de Larrea-Baz N, Chacón JI, García-Sáenz JA, Olier C, Muñoz M, Antón A, Sánchez Rovira P, Arcusa Lanza A, González S, Oltra A, Brunet J, Gavilá Gregori J, Martínez MT, Calvo L, Rosell L, Bezares S, Pastor-Barriuso R, Pérez-Gómez B, Martín M, Pollán M. Lope V, et al. Among authors: arcusa lanza a. Cancers (Basel). 2022 Sep 27;14(19):4705. doi: 10.3390/cancers14194705. Cancers (Basel). 2022. PMID: 36230628 Free PMC article.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Cross-sectional and longitudinal associations of adherence to WCRF/AICR cancer prevention recommendations with health-related quality of life in breast cancer survivors. Health-EpiGEICAM study.
Lope V, Guerrero-Zotano Á, Fernández de Larrea-Baz N, Antolín S, Benavent Viñuales M, Bermejo B, Ruiz-Moreno E, Baena-Cañada JM, París L, Antón A, Chacón JI, Muñoz M, García-Sáenz JA, Olier C, Sánchez Rovira P, Arcusa Lanza A, González S, Brunet J, Oltra A, Bezares S, Rosell L, Pérez-Gómez B, Pastor-Barriuso R, Martín M, Pollán M. Lope V, et al. Among authors: arcusa lanza a. J Nutr Health Aging. 2024 Aug;28(8):100312. doi: 10.1016/j.jnha.2024.100312. Epub 2024 Jul 5. J Nutr Health Aging. 2024. PMID: 38970849 Free article.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
Mel JR, Salar A, Rodríguez CA, Alegre A, González A, Cassinello J, Montesinos J, Gasquet JA, Sánchez J, Saigí E; AMG-DAR-2002-01 Study Group. Mel JR, et al. Curr Med Res Opin. 2008 Oct;24(10):2931-42. doi: 10.1185/03007990802381323. Epub 2008 Sep 4. Curr Med Res Opin. 2008. PMID: 18775103 Clinical Trial.